Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 12 2020
Historique:
pubmed: 23 10 2020
medline: 23 2 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

There is an unmet need for noninvasive biomarkers of intracranial pressure (ICP), which manifests as papilledema that can be quantified by optical coherence tomography (OCT) imaging. To determine whether OCT of the optic nerve head in papilledema could act as a surrogate measure of ICP. This longitudinal cohort study used data collected from 3 randomized clinical trials that were conducted between April 1, 2014, and August 1, 2019. Participants who were female and had active idiopathic intracranial hypertension were enrolled from 5 National Health Service hospitals in the UK. Automated perimetry and OCT imaging were followed immediately by ICP measurement on the same day. Cohort 1 used continuous sitting telemetric ICP monitoring (Raumedic Neurovent P-tel device) on 1 visit. Cohort 2 was evaluated at baseline and after 3, 12, and 24 months and underwent lumbar puncture assessment of ICP. Optical coherence tomography measures of the optic nerve head and macula were correlated with ICP levels, Frisén grading, and perimetric mean deviation. The OCT protocol included peripapillary retinal nerve fiber layer, optic nerve head, and macular volume scans (Spectralis [Heidelberg Engineering]). All scans were validated for quality and resegmented manually when required. A total of 104 women were recruited. Among cohort 1 (n = 15; mean [SD] age, 28.2 [9.4] years), the range of OCT protocols was evaluated, and optic nerve head central thickness was found to be most closely associated with ICP (right eye: r = 0.60; P = .02; left eye: r = 0.73; P = .002). Subsequently, findings from cohort 2 (n = 89; mean [SD] age, 31.8 [7.5] years) confirmed the correlation between central thickness and ICP longitudinally (12 and 24 months). Finally, bootstrap surrogacy analysis noted a positive association between central thickness and change in ICP at all points (eg, at 12 months, a decrease in central thickness of 50 μm was associated with a decrease in ICP of 5 cm H2O). In this study, optic nerve head volume measures on OCT (particularly central thickness) reproducibly correlated with ICP and surrogacy analysis demonstrated its ability to inform ICP changes. These data suggest that OCT has the utility to not only monitor papilledema but also noninvasively prognosticate ICP levels in idiopathic intracranial hypertension.

Identifiants

pubmed: 33090189
pii: 2772034
doi: 10.1001/jamaophthalmol.2020.4242
pmc: PMC7582233
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1264-1271

Subventions

Organisme : Department of Health
ID : NIHR-CS-011-028
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K015184/1
Pays : United Kingdom

Références

PLoS One. 2012;7(4):e34823
pubmed: 22536333
Neurology. 2013 Sep 24;81(13):1159-65
pubmed: 23966248
BMJ Open. 2019 Nov 7;9(11):e030882
pubmed: 31699727
NPJ Microgravity. 2020 Feb 7;6:7
pubmed: 32047839
Acta Neurochir (Wien). 2013 Nov;155(11):2141-8; discussion 2148
pubmed: 24018980
PLoS One. 2012;7(5):e36965
pubmed: 22615858
JMIR Res Protoc. 2017 Sep 18;6(9):e181
pubmed: 28923789
BMJ Open. 2017 Sep 27;7(9):e017426
pubmed: 28963303
J Neurol. 2017 Jul;264(7):1370-1380
pubmed: 28584914
JAMA Neurol. 2019 Sep 9;:
pubmed: 31498376
Transl Vis Sci Technol. 2020 Feb 21;9(3):24
pubmed: 32742754
Invest Ophthalmol Vis Sci. 2014 Nov 04;55(12):8173-9
pubmed: 25370513
Brain Commun. 2020 Jan 10;2(1):fcz050
pubmed: 32954315
Eye (Lond). 2014 Apr;28(4):390-8
pubmed: 24406417
Eye Brain. 2020 Jan 31;12:33-44
pubmed: 32099501
J Neurol Neurosurg Psychiatry. 1982 Jan;45(1):13-8
pubmed: 7062066
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1088-1100
pubmed: 29903905
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3872-83
pubmed: 27459664
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Front Neurol. 2019 Jul 24;10:798
pubmed: 31396151
J Neuroophthalmol. 2016 Mar;36(1):6-12
pubmed: 26618282
Invest Ophthalmol Vis Sci. 2012 Jun 29;53(7):4069-75
pubmed: 22599584
JAMA Ophthalmol. 2017 Apr 1;135(4):320-328
pubmed: 28241164
Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):723-30
pubmed: 20949278
Curr Opin Neurol. 2019 Jun;32(3):422-431
pubmed: 30865008
Ophthalmology. 2012 Jun;119(6):1250-7
pubmed: 22365058
Alzheimers Dement. 2016 Feb;12(2):154-163
pubmed: 26368321
BMC Ophthalmol. 2018 Jan 04;17(1):257
pubmed: 29298687
Cephalalgia. 2019 Feb;39(2):245-253
pubmed: 29911422
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):567-74
pubmed: 22592348
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3588-93
pubmed: 27388052
Arch Ophthalmol. 2010 Jun;128(6):705-11
pubmed: 20547947
BMJ Open. 2018 May 30;8(5):e020445
pubmed: 29848770
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223

Auteurs

Vivek Vijay (V)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Susan P Mollan (SP)

Birmingham Neuro-Ophthalmology, Ophthalmology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

James L Mitchell (JL)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Edward Bilton (E)

Birmingham Neuro-Ophthalmology, Ophthalmology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Zerin Alimajstorovic (Z)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

Keira A Markey (KA)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Anthony Fong (A)

Birmingham Neuro-Ophthalmology, Ophthalmology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Department of Medicine, The University of Queensland, Herston, Queensland, Australia.

Jessica K Walker (JK)

Birmingham Neuro-Ophthalmology, Ophthalmology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Hannah S Lyons (HS)

Birmingham Neuro-Ophthalmology, Ophthalmology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Andreas Yiangou (A)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Georgios Tsermoulas (G)

Department of Neurosurgery, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Kristian Brock (K)

Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Alexandra J Sinclair (AJ)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH